Pharmaceutical group Sanofi announced on Wednesday that the US Medicines Agency (FDA) had approved its drug Libtayo for the treatment of advanced skin cancer, in a statement. “Libtayo Receives Full Approval in Locally Advanced Basal Cell Carcinoma (CBC) and Expedited Approval in Metastatic CBC, Following Priority Review by Food and Drug Administration“(FDA) in the United States, said the French laboratory. He indicates that CBC is the most common skin cancer in the United States, “where nearly two million new cases are diagnosed each year».
Read also :Flu shots carry Sanofi
«Although the vast majority of basal cell carcinomas are diagnosed early and successfully treated with surgery or radiation therapy, a small proportion of tumors can reach an advanced stage and penetrate deeper into the tissue (locally advanced stage) or spread to other organs. (metastatic form), which makes them more difficult to treat», Specifies the French laboratory.
The Libtayo, developed with the Regeneron laboratory, “now approved for the treatment of the two most common advanced stage skin cancers in the United States», Indicates Sanofi. The laboratory indicates that it is continuing its research on “potential“From Libtayo in the treatment of other difficult-to-treat cancers,”starting with non-small cell lung cancer for which an FDA decision is expected at the end of February».
– .
